ST2 and mortality in non-ST-segment elevation acute coronary syndrome

American Heart Journal

Volumn 159, Issue 5, 2010, Pages 788-794

  Eggers, Kai M ^a   Armstrong, Paul W ^b   Califf, Robert M ^c   Simoons, Maarten L ^d   Venge, Per ^a   Wallentin, Lars ^a   James, Stefan K ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF ALBERTA   (Canada)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRINOGEN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; ST2 PROTEIN; TROPONIN T; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

ACUTE CORONARY SYNDROME; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE;

EID: 77951569359     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.02.022     Document Type: Article

References (23)

1. Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 13 (2007) 1598-1660
2. Morrow D.A., Cannon C.P., Jesse R.L., et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 53 (2007) 552-574
3. Blake G.J., and Ridker P.M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 41 4 Suppl S (2003) 37S-42S
4. Weinberg E.O., Shimpo M., De Keulenaer G.W., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106 (2002) 2961-2966
5. Shimpo M., Morrow D.A., Weinberg E.O., et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109 (2004) 2186-2190
6. Sabatine M.S., Morrow D.A., Higgins L.J., et al. Complementary roles of biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117 (2008) 1936-1944
7. Rehman S.U., Mueller T., and Januzzi J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52 (2008) 1458-1465
8. Boisot S., Beede J., Isakson S., et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Cardiac Fail 14 (2008) 732-738
9. Kakkar R., and Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7 (2008) 827-840
10. Simoons M.L., and GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357 (2001) 1915-1924
11. Ottervanger J.P., Armstrong P., Barnathan E.S., et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina. One-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV-Acute Coronary Syndrome) trial. Circulation 107 (2003) 437-442
12. James S.K., Siegbahn A., Armstrong P., et al. Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. Am Heart J 147 (2004) 267-274
13. Dieplinger B., Januzzi J.L., Steinmair M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chim Acta 409 (2009) 33-40
14. Levey A.S., Greene T., Kusek J.W., et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 (2000) 155A
15. Seki K., Sanada S., Kudinova A.Y., et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction though ST2 signaling. Circ Heart Fail 2 (2009) 684-691
16. Weir R.A., Miller A.M., Murphy G.E., et al. Serum soluble ST2. A potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 55 (2010) 243-250
17. Kuroiwa K., Arai T., Okazaki H., et al. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 284 (2001) 1104-1108
18. Brunner M., Krenn C., Roth G., et al. Increased levels of soluble ST2 protein and IG1 production in patients with sepsis and trauma. Intensive Care Med 30 (2004) 1468-1473
19. Oshikawa K., Kuroiwa K., Tago K., et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 164 (2001) 277-281
20. Tajima S., Oshikawa K., Tominaga S., et al. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 124 (2003) 1206-1214
21. Martinez-Rumayor A., Camargo C.A., Green S.M., et al. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol 130 (2008) 578-584
22. Bartunek J., Delrue L., Van Durme F., et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 52 (2008) 2166-2174
23. Miller A.M., Xu D., Asquith D.L., et al. IL-33 reduces the development of atherosclerosis. J Exp Med 205 (2008) 339-346